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Abstract.  Basic fibroblast growth factor, a potent an- 
giogenesis inducer,  stimulates urokinase (uPA) produc- 
tion by vascular endothelial cells. In both basic fibro- 
blast growth factor-stimulated and -nonstimulated 
bovine capillary endothelial and human umbilical vein 
endothelial cells single-chain uPA binding is mediated 
by a membrane protein with a Mr of 42,000.  Exposure 
of bovine capillary or endothelial human umbilical vein 
endothelial cells to pmolar concentrations of basic 
fibroblast growth factor results in a dose-dependent, 
protein synthesis-dependent increase in the number of 
membrane receptors for uPA (19,500-187,000) and in 
a parallel decrease in their affinity (KD  =  0.144-0.790 
nM).  With both cells,  single-chain uPA binding is 
competed by synthetic peptides whose sequence corre- 
sponds to the receptor-binding  sequence in the NH2- 
terminal domain of uPA. Exposure of bovine capillary 
endothelial cells to transforming  growth factor beta 1, 
which inhibits uPA production and upregulates type 1 
plasminogen activator inhibitor,  the major endothelial 
cell plasminogen activator inhibitor,  has no effect on 
uPA receptor levels. These results show that basic 
fibroblast growth factor, besides stimulating uPA 
production by vascular endothelial cells, also increases 
the production of receptors,  which modulates their ca- 
pacity to focalize this enzyme on the cell surface. This 
effect may be important in the degradative processes 
that occur during angiogenesis. 
M 
ANY physiological  and pathological  processes in- 
volving  tissue destruction and remodelling,  such 
as tumor invasion  and  angiogenesis,  require the 
coordinated action ofproteinases to degrade basement mem- 
brane  (BM) ~ and stromal  components.  Among these pro- 
teinases,  plasminogen  activators (PA) appear to play a cen- 
tral role (for reviews see Dane et al.,  1985; Moscatelli and 
Rifldn,  1988). The conversion  of plasminogen  to plasmin, 
and the ability of this  enzyme to activate,  in turn,  the se- 
creted zymogen form of PA (pro urokinase PA[uPA]) or sin- 
gle chain (sc) uPA, result in the local formation  of elevated 
concentrations of plasmin activity. While plasmin is able to 
degrade BM and stromal components, including fibronectin 
and laminin (Werb et al., 1980), it also activates prometallo- 
proteinases, the zymogen forms in which most metallopro- 
teinases are produced (Werb et al.,  1977; He et al.,  1989), 
as well as latent elastase (Chapman  and Stone,  1984). 
The modulation of plasmin formation and activity, and its 
localization in the extracellular  environment are regulated by 
complex control mechanisms (for a review, see Saksela and 
Rifkin, 1988). Cellular PA synthesis, which directly controls 
the extracellular  PA level,  is affected by many hormones, 
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growth  factors,  cyclic  nucleotides,  and  tumor  promoters 
(Dane et al.,  1985; Moscatelli and Rifkin,  1988).  The ex- 
tracellular PA activity is also modulated by specific PA inhib- 
itors. These included the PA inhibitor  type 1 (PAI-1), which 
is the major PA inhibitor  produced by vascular  endothelial 
cells (Loskutoff and Edgington,  1977; Hekman and  Los- 
kutoff, 1985), the PA inhibitor type 2 (PAI-2) (Kawano et al., 
1970; Astedt et al.,  1985; Kruithof et al.,  1986),  and pro- 
tease nexin I (PN I) (Baker et al., 1980; Eaton et al., 1984). 
These locally produced inhibitors,  often synthesized by the 
same cells that produce PAs, play a central  role in limiting 
PA. In addition,  high affinity membrane receptors for PA and 
plasminogen have been shown to focalize the proteolytic ac- 
tivity at cell-substratum contact sites (Vassalli et al.,  1985; 
Stoppelli et al.,  1985; Cubellis et al.,  1986; Hajjar et al., 
1986; Plow et al., 1986; Appella et al., 1987; Neilsen et al., 
1988). Thus it is currently believed that most extracellular 
proteolytic activity is strictly  limited to specific pericellular 
sites. 
uPA receptors have been described on a number of cells, 
including  the macrophage-monocyte-like U937 cells,  en- 
dothelial  cells, fibroblasts,  polymorphonuclear leukocytes, 
tumor cell lines, and tumor explants (Stoppelli  et al., 1985; 
Vassalli et al.,  1985;  Blasi et al.,  1987).  The cloning  and 
purification  of the uPA receptor of U937 cells have shown 
that  it is a polypeptide with a Mr of 35,000  that  is highly 
glycosylated.  The relative  molecular weight of the mature, 
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cell lines (Behrendt et al., 1990; Estreicher et al., 1989; Haj- 
jar and Hamel,  1990;  Nielsen et al.,  1988;  Roldan et al., 
1990).  The uPA receptor is a membrane protein that can 
bind both the active two-chain form ofuPA and its zymogen, 
single-chain form, pro uPA or scuPA (Cubellis et al., 1986). 
Binding of  both forms is mediated by an amino acid sequence 
encompassing residues  13-30  of the NH2-terminal,  EGF- 
like domain of the noncatalytic A chain of uPA (Appella et 
al.,  1987).  Thus, the bound enzyme is catalytically active, 
and bound pro uPA can be activated by plasmin (Cubellis et 
al., 1986). The interaction of uPA with its receptor has been 
shown to be species specific: homologous uPA binds human 
or murine cells, whereas the heterologous enzyme does not 
(Estreicher et al., 1989). Besides localizing plasminogen ac- 
tivation on the cell surface, binding of uPA and pro uPA to 
the uPA receptor also results in a 16-fold acceleration in the 
activation of cell-bound plasminogen. This is probably be- 
cause of a concentration effect of both uPA and plasminogen 
on the cell surface, and to an acceleration of the feedback 
activation of pro uPA by membrane-bound plasmin (Ellis et 
al., 1989). Unlike most membrane receptors, the uPA recep- 
tor is not internalized or down regulated after ligand binding. 
Urokinase dissociates very slowly from its receptor and re- 
mains active on the cell surface for several hours (Vassalli 
et al.,  1985).  However,  interaction of receptor-bound uPA 
with PAI-1 has recently been shown to cause a rapid inter- 
nalization and degradation of the enzyme (Cubellis et al., 
1990).  This may provide a mechanism of clearing inactive 
uPA from the cell surface. Thus, binding ofuPA to a cell sur- 
face receptor not only focalizes the activity at cell-substra- 
tum contact sites but also provides a mechanism for the regu- 
lation of extracellular proteolysis. 
Few agents are known to modulate expression of the uPA 
receptor in monocytes and epithelial cells. Differentiation of 
U937  cells by PMA causes a marked increase in receptor 
number and a parallel decrease in receptor affinity (Picone 
et al., 1989; Stoppelli et al., 1985). A similar phenomenon 
has been described in HeLa cells treated with PMA or EGF 
(Estreicher  et  al.,  1989).  Interferon  gamma  and  tumor 
necrosis factor alpha increase the number of receptors, with- 
out any change in receptor affinity, respectively, in U937 (Lu 
et al., 1988) and peripheral blood monocytes (Kirchheimer 
et al.,  1988).  The polarization of uPA receptors on mono- 
cytes and U937 cells placed in a chemotactic gradient (Es- 
treicher et al.,  1990) indicates an additional mechanism of 
modulation and strengthens the hypothesis of a role of the 
uPA receptor in cell migration and invasion. 
The stimulation of uPA and plasmin activities has been 
proposed  to  be  a  component of the angiogenic response 
(Mignatti et al., 1989). Consistent with this hypothesis is the 
observation that basic fibroblast growth factor (bFGF), a po- 
tent angiogenic factor (Rifldn and Moscatelli,  1989),  dra- 
matically upregulates uPA expression in endothelial cells 
(Saksela et al., 1987; Pepper,  1990). On the contrary, trans- 
forming growth factor beta 1 (TGFBI), which may be an in- 
hibitor of  angiogenesis, is a potent inhibitor of uPA synthesis 
and one of the most effective inducers of PAI-1 production 
(Saksela et al., 1987; Pepper,  1990). In the light of previous 
data showing the involvement of uPA and uPA receptors in 
tumor  invasion  and  angiogenesis  (Mignatti et  al.,  1986, 
1989;  Ossowski,  1988;  Pepper,  1990),  understanding the 
role played by bFGF and TGFB1 in the expression of  the uPA 
receptor in vascular endothelial cells is of  particular interest. 
The results presented in this paper show that, while TGFB1 
has  no  effect,  bFGF  concentrations  that  stimulate  uPA 
production cause up to a  10-fold increase in the number of 
endothelial cell receptors for uPA. 
Materials and Methods 
Growth Factors and Reagents 
Recombinant bFGF was a generous gift from Synergen, Inc. (Boulder, CO). 
Porcine platelet "I'GF~I was purchased from R&D Systems (Minneapolis, 
MN). Human scuPA was a kind gift from Dr. Jack Henkin (Abbott Labora- 
tories,  Chicago,  IL).  The  synthetic peptides  [ala 19]  uPA  12-32,  corre- 
spending to the receptor-binding sequence of human uPA, and [ala 2°] uPA 
13-33, corresponding to the receptor-binding sequence of mouse uPA (Ap- 
pella et al., 1987),  were generous gifts from Drs. Francesco Blasi (Univer- 
sity of Copenhagen, Copenhagen, Denmark) and Ettore Appella (National 
Institutes of Health). Human uPA was purchased from Leo Pharmaceuticals 
(Copenhagen, Denmark). Bovine uPA was partially purified from MDBK 
cells. Details of the purification procedure axe to be published elsewhere 
(Sate, Y., L. Odekon, and D. R/fkin, manuscript in preparation). The ma- 
terial  used in  the experiments described was  further purified by bepa- 
rin-Sepharose chromatography and was estimated to be •80%  pure, with 
asp act of 2 Ploug U//~g. Bis (Sulfosuccinimidyl) Suberate (BS  3) was pur- 
chased from Pierce Chemical Co. (Rockford, IL). Aprotinin (Trasylol) and 
cyclobeximide  were purchased from Sigma Chemical Co. (St. Louis, MO). 
Cells and Culture Conditions 
Bovine capillary endothelial (BCE) cells were isolated from the adrenal cor- 
tices of yearling calves as described (Folkman et al., 1979),  and grown in 
gelatin-coated Petri dishes in alpha minimum essential medium (aMEM; 
Gibco Laboratories, Grand Island, NY) supplemented with 5 % donor calf 
serum (CS; Flow Laboratories, McLean, Virginia) and 2 mM L-glntamine 
(Gibco Laboratories). The cells used in the experiments described were 
from the low bFGF producer clone 8A2 (Tsuboi et al., 1990), and were used 
between passages 14 and 18. For uPA-binding assays confluent cultures were 
washed once with serum-free medium and incubated for  16 h  in DME 
(Gibco) containing 1% CS plus or minus the indicated concentrations of 
bFGF, TGF~I, or combinations thereof. Human umbilical vein endothelial 
ceils (HUVEC), obtained from umbilical cords (Hajjar and Hamel, 1990), 
were a kind gift of Dr. Richard Levin (Bellevue Hospital, New York). The 
cells were grown in RPMI 1640 medium supplemented with 10% FCS (Pc- 
heis Intergen, Purchase, NY) and bFGF (4 ng/ml), and were refer every 
fourth day.  For uPA-binding assays cultures that had been confluent for 
6 d without medium change were incubated for 16 h in RPMI 1640 medium 
supplemented with 5 % FCS and bFGF (10 ng/ml). Control, nonstimulated 
cultures were incubated in the same medium without bFGE 
Radioiodination of scuPA 
80 #g of scuPA were iodinated with 2 mCi of Na125I (New England Nu- 
clear, Boston, MA) and 1.6 ~g of lodogen (Pierce Chemical Co.) for 20 rain 
at room temperature. The reaction was stopped by addition of excess [] and 
Na-metabisulfite. The reaction mixture was loaded onto a  0.5-ml hepa- 
rin-Scpharose column (Andrade-Gordon and Strickland,  1986) equilibrated 
with 0.01 M Tris-HCl, 1 mg/ml BSA, pH 7.5. After extensive washing with 
0.2 M NaCI in 0.01 M Tris-HC1,  0.05%  Tween 80, pH 7.5, the iodinated 
scuPA was eluted with 1.0 M NaCI in the same buffer.  The eluted material 
was 9%99%  TCA precipitable, and had a sp act of 0.21  /zCi/pMole. 
Binding Assay with Cold uPA 
Confluent bovine capillary endothelial (BCE) cells in 35-mm Pctri dishes 
were washed twice with PBS and acid treated with 50 mM glycine-HCl, 
0.1 M NaC1, pH 3.0, for 3 rain at room temperature with mild shaking. After 
neutralization with halfa volume of 0.5 M Hepes, 0.1 M NaCI, pH 7.5, the 
cultures were washed three times with PBS containing BSA (1 mg/ml). 16 
Plong U per dish of either partially purified bovine uPA (BuPA) or pure hu- 
man uPA (HuPA) were then added in I ml of  ice-cold binding medium, con- 
sisting of DME supplemented with 20 mM Hepes and BSA (1 rag/m1), and 
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times with PBS-BSA and incubated with 400 pl/dish of 50 mM glycine- 
HCI, 0.1 M NaC1, pH 3.0 for 3 min at room temperature with constant shak- 
ing. The acid wash was collected, and the cells were rinsed briefly with 400 
pl/dish of the same acid solution. The two acid washings were combined 
and immediately tested for PA activity by both the ~2sI-fibrin  assay and by 
zymography as previously described (Gross et al.,  1982;  Saksela  et al., 
1987). 
Binding Assay with uJl-scuPA 
Confluent BCE cells in 35-mm dishes were washed with PBS and acid 
treated as described above, and incubated at 4°C for 1 h with 500 #1 of bind- 
ing medium containing Aprotinin (100  pg/ml) and either  11  /xl of the 
[ala  19] uPA  12-32 peptide (903 ~g/ml), 7.4 pl of the [ala  2°] mouse uPA 
13-33 peptide (1,343 pg/mi), or 11 pl of H20. At the end of the incubation 
12SI-scuPA (0.2 ILCi) was added to the dishes in 500 ~tl of binding medium 
containing Aprotinin (100 pg/ml), and the incubation was continued for 
1 h. After removing the medium, the cells were washed four times with 
1 ml/dish of PBS-BSA, and the cell layer was lysed with 100 pi of 0.5% 
Triton X-100 in 0.1 M Tris-HCl, pH 8.1. The radioactivity associated with 
the binding medium, PBS-BSA washings and the cell lysates was measured 
in a gamma counter. 2 ttl aliquots of the cell lysates were tested for PA activ- 
ity by the ~25I-fibrin  assay (Gross et al.,  1982) and for protein concentra- 
tion by the BCA protein assay reagent (Pierce Chemical Co.) using BSA as 
a standard. The remaining lysate was electrophoresed in a 10% SDS-POly- 
acrylamide gel. 
Cross-linking of U~I-scuPA to BCE Cells 
At the end of the incubation at 4°C with 125I-scuPA, 10 pl of BS  3 (100 mM) 
in DMSO were added to the binding medium in the culture dishes. The cul- 
tures were incubated at room temperature for 20 rain with constant shaking. 
After the medium was removed and the cells were washed with PBS-BSA 
as described above, the cells were scraped with a rubber policeman, lysed 
with 100 pl of2x nonreducing La6mmli buffer (La~mmli, 1970), and soni- 
cated. The cell lysates were electrophoresed in an SDS/5-10% polyacryl- 
amide gradient gel. 
Cross-linking of Uq-scuPA to Detergent Phase 
Cell Extracts 
Confluent BCE cells of HUVECs in either 60- or 100-ram Petri dishes were 
washed once with PBS, detached with a rubber policeman, and resuspended 
in PBS with a Pasteur pipette to obtain a single-cell  suspension.  After cen- 
trifugation the cells were resuspended in 10 mi ofSO mM glycine-HCl, 0.1 M 
NaCI, pH 3.0, and incubated at room temperature for 3 min. The acid treat- 
ment was stopped by addition  of  5 ml of  0.5 M Hepes, 0.1 M NaCI, pH 7.5. The 
cells were counted with a hemocytometer, centrifuged, and resuspended in 
ice-cold 0.1 M Tris-HCl, pH 8.1, containing 1% Triton X-114, EDTA (10 
mM), Aprotinin (10/~g/ml), and PMSF (1 mM) (lysis buffer). The volume of 
the lysis buffer was adjusted so as to have the same cell concentration in all the 
samples. Detergent phase separation (Bordier,  1981) was achieved after 15 
rain at 37°C, and was repeated twice.  At the end of the second separation, 
0.25 % CHAPS was added, and the samples were centrifuged at 2,000 g for 15 
min at 4°C.  80/~1 of the supernatant containing membrane proteins were 
mixed with 2.2/~1  of  the [ala  19] human uPA 12-32 peptide (903/~g/ml),  1.5 #1 
of the [ala  2°] mouse uPA 13-33 peptide (1,343/~g/ml), or 2.2 pl of H20, and 
incubated at 40C for 1 h with constant shaking.  2 pl (0.30 pMoles) of 12sI- 
scuPA were then added, and the incubation was continued for 1 h under the 
same conditions. As a control, 2 t~l of 12SI-scuPA  were diluted in 80 pl of lysis 
buffer  plus 2.2 ttl of  H20, and treated as all the samples. At the end of  the incu- 
bation, 1.5 pl ofBS  3 in DMSO (100 mM) were added, and the samples were 
incubated at room temperature for 15 rain with constant shaking. The cross- 
linking reaction was stopped by adding 20 pi of4x nonreducing La~mmli 
buffer. The samples were finally electrophoresed  in an SDS/5-10 % polyacryl- 
amide gradient gel. Dried gels were exposed to X-OMAT  TM AR films (East- 
man Kodak Co., Rochester,  NY). 
Single Cell Caseinolytic Plaque Assay 
Sparse BCE cell cultures (1.5  ×  104 cells/cm2),  grown overnight in the 
presence or absence of 10 ng/ml of bFGF, were acid treated and prein- 
cubated with binding medium +  20/~g/mi of the [ala  2°] mouse uPA 13-33 
peptide, as described above.  16 Ploug U/ml of semipure bovine uPA were 
then added for 1 h at 4°C.  After removing the medium, the cultures were 
washed five times with PBS-BSA and overlaid with binding medium sup- 
plemented with 0.8% agar,  1.5% nonfat dry milk, and 60 #g/ml of human 
plasminogen. Proteolytic plaques were scored microscopically  after 3 h of 
incubation at 37"C. 
Results 
To test if bFGF increases the uPA binding capacity of BCE 
cells confluent monolayers of  control and bFGF-treated BCE 
cells were washed with 50 mM glycine-HC1, pH 3.0, as de- 
scribed in Materials and Methods, and incubated with either 
BuPA or HuPA for 1 h at 4°C. At the end of the incubation, 
the cells were acid washed a second time and the uPA recov- 
ered was  analyzed by zymography.  The endogenous cell- 
bound  PA  activity,  which  was  recovered in the  first acid 
wash,  before the  cells  were  exposed  to  exogenous uPA, 
migrated  primarily  as  105-110,000  Mr  bands  (data  not 
shown). Zymography of the material recovered after the sec- 
ond acid wash  revealed the presence of bands that eomi- 
grated with either BuPA (45,000 Mr), or HuPA (50,000 Mr), 
as well as  105-110,000-Mr  bands,  which represented uPA- 
PAI-1 complexes. The intensity of  both the high and low rela- 
tive molecular weight bands detected in the first and in the 
second acid wash increased with increasing bFGF concen- 
trations. Thus, although a significant part of the binding ca- 
pacity of the BCE cells was because of formation of SDS- 
resistant complexes with PAI-1, uPA also bound reversibly to 
cell membrane or extracellular matrix components whose 
expression was  up-regulated by bFGF.  This resulted in a 
significant increase of cell-bound uPA. 
The material eluted from the ceils with the second acid 
wash, containing the cell-bound exogenous uPA, was quanti- 
tated by the t2sI-fibrin plate assay. The results  (Fig.  1) showed 
that (a) the amount of HuPA bound to BCE ceils under the 
conditions tested was comparable to the amount of BuPA 
bound;  (b) bFGF increased the binding of both BuPA and 
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Figure 1. Binding of BuPA and HuPA to control and bFGF-treated 
BCE cells.  Confluent BCE cells,  incubated overnight with either 
control medium or medium containing the indicated concentrations 
of bFGF, were acid washed and incubated with 16 Ploug U of semi- 
pure BuPA or pure HuPA for 1 h at 4°C. At the end of the incubation 
the cell-bound uPA was  removed as described  in Materials and 
Methods and its activity was measured by the 125I-fibrin assay. (tJ) 
bovine uPA; (=) human uPA. 
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uPA  binding  capacity  of  BCE 
cells.  ~2SI-scuPA was  bound  to 
confluent BCE ceils treated with 
the  indicated  concentrations  of 
bFGF as described in Materials 
and Methods.  Cell lysates were 
run  in  an  SDS/10% polyacryl- 
amide gel under reducing (R) and 
nonreducing  conditions.  (NR), 
and then analyzed by autoradiog- 
raphy. 
HuPA up to  five-fold in  a  dose-dependent manner.  Thus, 
pure HuPA could be used for studying binding to BCE cells. 
To avoid the possible contribution of uPA bound to PAI-1 
in our measurements,  experiments were carried out using 
~I-labeled human single chain uPA (~I-scuPA), as this form 
ofuPA is not bound by PAL1 (Hekman and Loskutoff, 1985.). 
This ligand was bound to control BCE cells or cells treated 
with increasing concentrations of bFGF in the presence of 
Aprotinin, as described in Materials and Methods. Cell ly- 
sates prepared with 0.5 % Triton X-100 were then analyzed 
by SDS-PAGE under reducing and nonreducing conditions, 
followed by autoradiography. As shown in Fig. 2, under both 
reducing and nonreducing conditions, bound t25I-scuPA mi- 
grated as a single band with a relative molecular weight of 
47,000, whose intensity in the autoradiogram increased with 
increasing bFGF concentrations. No formation of SDS-re- 
sistant uPA-PAI-1 complexes occurred under the experimen- 
tal conditions used. Slices of the polyacrylamide gel corre- 
sponding to the bands in the autoradiogram were cut out, 
and the associated radioactivity was measured in a gamma 
counter. As shown in Fig. 3, the radioactivity associated with 
the bands  increased  with bFGF  concentration in  a  dose- 
dependent manner.  10 ng/ml of bFGF induced a three-fold 
increase in t25I-scuPA binding relative to control medium. 
Aliquots of the cell lysates run in the.gel were also tested for 
PA  activity and  for protein concentration.  Basic  FGF in- 
creased the specific PA activity of the cell lysates from 12.8 
mU/#g of protein in control cells to 176.9 mU/#g of protein 
in the cells treated with 10 ng/ml of bFGE On the contrary, 
the protein concentration of the cell lysates only increased 
from 1.36  mg/ml in control cultures to  1.72 mg/ml in the 
cells treated with  10 ng/ml of bFGF.  Thus,  the increased 
t2SI-scuPA binding was not because of a significant increase 
in cell number in the cultures treated with bFGE Although 
the effect of bFGF on the production of PA  activity was 
significantly higher than the effect on the binding capacity of 
the BCE cells, the two dose-response curves were superim- 
posable, showing that modulation of PA production and of 
the PA binding capacity occurred in the same range of bFGF 
concentrations. 
TGF/31 antagonizes the effect of bFGF on'PA production 
by capillary endothelial ceils (Saksela et al.,  1987). To test 
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Figure 3. Effect of bFGF on the 125I-scuPA  bind- 
ing capacity and PA activity of BCE ceils. Slices 
of  the gel corresponding to the reduced and nonre- 
duced bands revealed by autoradiography shown 
in Fig. 2 were cut out and the associated radioac- 
tivity was measured in a gamma counter (,,). Ali- 
quots of the cell extracts used for the t2SI-scuPA 
binding assay were tested for PA activity by the 
t25I-fibrin assay (zx). Values on the right ordinate 
are Ploug U/mg of protein, as determined by refer- 
ence to a HuPA standard curve. The range of vari- 
ability for each point did not exceed 5 % of the val- 
ues reported. 
whether TGFfll also affected the uPA binding capacity of 
BCE cells we assayed the scuPA binding capacity of BCE 
cells incubated with either TGF/31 (10 ng/ml) or bFGF (1 
ng/ml) plus TGFB1 (10 ng/ml). At this concentration TGFI31 
completely abolishes the stimulatory effect of bFGF on the 
PA production of BCE cells (Saksela et al., 1987). As shown 
in Figure 4 A,  while bFGF induced a 2.5-fold increase in 
12~I-scuPA binding to BCE cells, TGF/~I had no effect either 
when it was tested alone or in the presence of bFGE On the 
contrary, the PA activity present in the cell lysates used for 
the binding assay was dramatically reduced by TGFB1 under 
both conditions (Figure 4 B). Since TGF~ significantly in- 
creases expression of PAI-1 in  BCE cells  (Pepper et al., 
1990; Saksela et al.,  1987), the lack of an observed inhibi- 
tory effect of TGFB1 might result from a balance between a 
decreased synthesis of uPA receptor and increased surface 
binding of uPA-PAI-1 complexes to a second site. Therefore, 
we tested the specificity of nSI-scuPA binding to BCE cells 
by competing n~I-scuPA with the [ala  2°] uPA 13-33 peptide, 
corresponding to the receptor-binding sequence of mouse 
uPA (Appella et al.,  1987).  Preliminary experiments (not 
shown) had indicated that binding of human scuPA to BCE 
cells could be completed by both the [ala  19] uPA 12-32 pep- 
tide, corresponding to the receptor-binding sequence of hu- 
man uPA, and by the [ala  2°] mouse uPA 13-33 peptide. The 
latter was actually a more efficient competitor. As shown in 
Fig. 4 A, >97%  of the ~25I-scuPA binding to either control 
cultures or cultures treated with bFGE TGFB1, or both growth 
factors could be inhibited by an excess of cold competitor. 
Thus, ~2SI-scuPA binding to both bFGF- and TGFBl-treated 
cells occurred through a  specific sequence of its NH2-ter- 
minal, noncatalytic domain, and did not involve interactions 
between the enzyme active site and PAI-1. 
The scuPA-binding component was further characterized 
by cross-linking experiments after binding of 125I-scuPA to 
bFGF- and TGF/5'l-treated cells. The autoradiogram of the 
cell extracts after SDS-PAGE (Fig. 5) revealed the presence 
of a band with a relative molecular weight of •100,000  in 
control cells and in cells treated with bFGF, TGFBI, or a 
combination of both growth factors. This is the expected po- 
sition of the uPA receptor-scuPA complex (Estreicher et al., 
1989). The intensity of this band increased with increasing 
bFGF concentrations and was not affected by TGF~. For- 
mation of the  100,000-M, complex band was abolished by 
an  excess of either the  [ala  2°]  mouse uPA  13-33  peptide 
and, to a somewhat lesser extent, by the [ala  i~] uPA 12-32 
peptide. 
The uPA receptor has recently been purified and cloned 
(Roldan et al.,  1990; Behrendt et al.,  1990), and shown to 
be a cell membrane protein. To verify whether the BCE cell 
receptor for uPA is also a membrane protein, control cells 
and cells treated with bFGF were lysed in Triton X-114 and 
the membrane components were extracted by temperature- 
induced detergent phase separation (Bordier, 1981). Binding 
of ~25I-scuPA and subsequent cross-linking were then per- 
formed on detergent phase extracts as described in Materials 
and Methods. The autoradiogram of the cross-linked cell ex- 
tracts (Fig. 6) showed that in both control and bFGF-treated 
samples ~25I-scuPA formed a complex with a cell membrane 
component that migrated in SDS-PAGE as a broad band with 
a relative molecular weight of '~100,000.  The intensity of 
this band was 3.6-fold higher in bFGF-treated than in control 
cells, nSI-scuPA-receptor complex formation was abolished 
by competing 125I-scuPA with a 3,000-fold molar excess of 
the [ala  2°] mouse uPA 13-33 peptide. The same concentra- 
tion of the [ala '9] HuPA 12-32 peptide competed 125I-scuPA 
for binding to bFGF-treated cells by over 80%. Similar re- 
sults were obtained with detergent phase extracts of HUVECs 
(Fig.  6).  With these cells the  125I-scuPA receptor complex 
also  migrated as  a  single band  with  a  relative molecular 
weight of ,~100,000.  This band was two-fold more intense in 
bFGF-treated than in control cells.  The [ala  19] HuPA  12- 
32 peptide reduced the amount of the  100,000°Mr  complex 
formed in bFGF-treated cell extracts to '~50% of the amount 
formed in control cell extracts. The [ala  2°] mouse uPA 13- 
33 peptide abolished the increased uPA binding observed in 
bFGF-treated ceils but did not affect the level of binding in 
control cells. 
The bFGF-induced increase in  t25I-scuPA receptor com- 
plex formation could result from several different mecha- 
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Figure  4.  Effect of BFGF and  TGF/31 on  t25I-scuPA binding  to 
BCE cells.  (A) ~25I-scuPA  binding to confluent BCE cells treated 
with the indicated concentrations  of bFGF and TGF/31 was mea- 
sured as described in Materials and Methods. The specificity of the 
binding was determined by competition with a 3,000-fold molar ex- 
cess of the [ala  2°] mouse uPA 13-33 peptide (I). (B) PA activity 
of the samples shown in A. Values in the ordinate show ~25I-fibrin 
degradation products released in l-h incubation. Error bars: range 
of variability in duplicate samples. Samples in the presence of the 
[ala  2°] mouse uPA 13-33 peptide were not tested. 
incubated with BuPA. Virtually no proteolytic plaques were 
observed in the presence of a 3,000-fold molar excess of the 
late [ala  20] mouse uPA 13-33 peptide and very faint plaques 
in  the  presence  of the  same  amount  of the  [ala tg]  HuPA 
12-32 peptide. Plaques formed in the bFGF-treated cultures 
were much larger than in control dishes; however, the num- 
ber of cells forming plaques was not increased. Thus, essen- 
tially all BCE cells possess uPA receptors. This ruled out the 
possibility  that  the  bFGF-induced  increase  in  ~25I-scuPA 
binding was because of expression of the uPA receptor by 
BCE cells devoid of it in  the absence of bFGF. 
To test whether the effect of bFGF was because of an in- 
crease in receptor number or affinity,  t25I-scuPA binding to 
control BCE ceils and cells treated with bFGF (10 ng/ml) 
was measured in the presence of increasing 125I-scuPA con- 
centrations. The specificity of the binding was determined by 
competing ~2q-scuPA with a  10-fold excess of cold scuPA. 
Scatchard analysis of the data obtained (Fig.  8) revealed a 
single class of receptors in both control and bFGF-treated 
cells.  The number of binding  sites increased from 1.95  × 
nisms of action: (a) bFGF might increase the synthesis of the 
uPA receptor; (b) it might increase the affinity of the receptor 
for the ligand; and (c) it might induce the production of uPA 
receptors in cells normally devoid of them in the absence of 
the growth factor. To discriminate among these possibilities, 
confluent BCE cells were incubated overnight with bFGF in 
the absence or in the presence of cycloheximide. As shown 
in Fig. 7, both 2 and 10 #g/ml of cycloheximide lowered the 
level of ~5I-scuPA  binding below that of control BCE cells 
and  completely abolished  the  stimulatory effect of bFGE 
This indicated that the bFGF-induced increase in 125I-scuPA 
binding  requires  protein  synthesis.  To  determine  if  the 
proportion of cells expressing uPA receptors was altered by 
bFGF, the binding of partially purified BuPA was analyzed 
by casein overlay assay of sparse BCE cell cultures as de- 
scribed in Materials and Methods. The microscopic analysis 
of single cell proteolytic plaques (data not shown) revealed 
the presence of proteolytic plaques around most of the cells 
Figure  5.  Cross-linking  of ~25I-scuPA to BCE  cells  treated  with 
bFGF and TGF/31. Confluent BCE ceils were incubated for 16 h 
with the  indicated concentrations  of bFGE or with  10 ng/ml of 
TGF~I +  1 ng/ml of bFGE 125I-scuPA  was bound to the cells in 
the presence or absence of the [ala 19] human uPA 12-32 peptide or 
the [ala  2°] mouse uPA 13-33 peptide and cross-linked as described 
in Materials and Methods. Cell lysates were run in an SDS/5-10% 
gradient polyacrylamide gel and analyzed by autoradiography. 
The Journal of Cell Biology, Volume 113,  1991  1198 Figure 6. Cross-linking of ~2~I-scuPA  to detergent phase extracts of bFGF-treated BCE cells and HUVECs. (U) '2SI-scuPA incubated and 
cross-linked in the absence of cell extracts; (1) control cells; (2) cells stimulated with bFGF (10 ng/ml); (3-4) cells treated with bFGF 
(10 ng/ml) and bound to ~2SI-scuPA  in the presence of a 3,000-fold molar excess of the [ala ~9] HuPA 12-32 peptide (3) or the [ala  2°] mouse 
uPA 13-33 peptide (4). 
104  sites/cell  in  control  cells  to  1.88  x  104  sites/cell  in 
bFGF-treated cells. The receptor affinity for the ligand de- 
creased  respectively from  Ko  =  0.144-0.790  nM.  Thus, 
bFGF stimulated the synthesis of uPA receptor in BCE cells 
by 10-fold, while lowering receptor affinity for its ligand by 
five-fold. This resulted in the two- to threefold inccease in 
the  uPA  binding  capacity observed  in  bFGF-treated BCE 
cells. 
Discussion 
The data presented show that bFGF, at concentrations that 
stimulate uPA production, also enhances the expression of 
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Figure 7. Effect of cycloheximide on the ~2SI-scuPA  binding capac- 
ity of  bFGF-treated  BCE cells. Confluent BCE cells were incubated 
for 16 h with 10 ng/ml ofbFGF +  2 or 10 #g/ml of cycloheximide. 
At the end of the incubation ~2SI-scuPA  binding was determined in 
the absence (~) or in the presence (m) of the [ala2o] mouse uPA 
13-33 peptide as described in Materials and Methods. 
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Figure 8.  Scatchard plot of ~2SI-scuPA  binding  to control  (e) and 
bFGF-stimulated BCE  cells (&).  Control cells and cells treated 
with bFGF (10 ng/ml) were acid washed as described in Materials 
and Methods and incubated with increasing concentrations (from 
10 pM to  10 nM) of ~:SI-scuPA in 1 ml of binding medium. For 
each concentration of ~2SI-scuPA  nonspecific binding was deter- 
mined by competition with a 100-fold molar excess of cold scuPA. 
Under these conditions, with the lowest concentration ~2SI-scuPA 
used (10 pM) the concentration of cold ligand was 1 riM, and there- 
fore about the estimated KD for the bFGF-treated ceils (0.790 nM). 
In all the other samples the concentration of cold scuPA was at least 
3.8-fold  higher than the estimated KD.  Binding assay conditions 
were the same as described in Materials and Methods. 
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trary,/31  has no effect on the expression of the uPA receptor 
in these cells. 
Several lines of evidence demonstrate that uPA binding to 
vascular endothelial cells is mediated by a cell membrane 
receptor that has the same characteristics as those previously 
described in monocytes and several tumor lines (Roldan et 
al.,  1990;  Behrendt et al.,  1990;  Estreicher et al.,  1989). 
Uroldnase binding to both BCE cells and HUVECs (a) does 
not require a catalytically active site; (b) involves a specific 
receptor-binding sequence in the NH2-terminal  domain of 
uPA; (c) is mediated by a membrane protein, whose relative 
molecular weight of ,o42,000 is similar to the relative mo- 
lecular weight of the receptor described in U937 and HeLa 
cells (45,000  +  5,000)  and HUVECs (48,000)  (Hajjar and 
Hamel, 1990); and (d) the number of uPA receptors per cell 
in BCE cells (19,500)  and their affinity (Kd =  0.144  nM) 
are of the same order of magnitude as the values reported for 
other cell lines (Blasi,  1988).  Recently, Hajjar and Hamel 
(1990) have described a uPA receptor in HUVECs that medi- 
ates binding to a  domain of uPA different from its NH2- 
terminal domain. In our experiments 125I-scuPA binding to 
HUVECs  was competed by the [ala 19] human uPA  12-32 
peptide and, although to a lesser extent, also by the [ala  2°] 
mouse uPA  13-33  peptide. This shows that under our ex- 
perimental  conditions  uPA  binding  was  mediated  by  its 
NH2-terminal domain. 
It is interesting to note that binding of human scuPA to 
BCE cells and HUVECs was competed by both the [ala 19] 
HuPA 12-32 peptide and the [ala  2°] mouse uPA 12-32 pep- 
tide. The latter was actually more effective than the former 
in competing with human scuPA for binding to BCE cells. 
While this result may reflect relative evolutionary distances 
between human, mouse, and bovine, it also indicates that the 
reported species specificity of the uPA receptor interaction 
(Estreicher et al., 1989; Appella et al., 1987) may not be ab- 
solute. In fact, bovine cells appear to bind HuPA as well as 
BuPA. 
Basic FGF  increases  the uPA-binding  capacity of BCE 
cells through a protein synthesis-dependent mechanism that 
results in a 10-fold increase in receptor number per cell and 
a parallel five-fold decrease in receptor affinity  for its ligand. 
The effect of bFGF is neither mediated by an increase in cell 
number nor because of expression of the uPA receptor by 
elements of the cell population devoid of uPA receptor in the 
absence of the growth factor. A similar increase in receptor 
number per cell and decrease in receptor affinity has also 
been  described  in  U937  cells  stimulated with  PMA  and 
HeLa cells treated with EGF (Estreicher et al., 1989; Picone 
et al., 1989; Stoppelli et al., 1985). The lower affinity of the 
uPA receptor in bFGF-stimulated endothelial cells may be 
because of posttranslational modification, as has been pro- 
posed for PMA-stimulated U937 cells (Picone et al., 1989). 
The uPA receptor is a highly glycosylated protein (Behrendt 
et al.,  1990).  Thus, qualitative and quantitative modifica- 
tions of its glycosylation may significantly affect its affinity 
for the ligand.  In our experiments the relative molecular 
weight of the l"I-scuPA-receptor complex in SDS-PAGE ap- 
peared to be similar in bFGF-treated and -untreated cells 
when analyzed in an SDS/5-10%  polyacrylamide gradient 
gel. A more precise characterization (e.g., by 2D electro- 
phoresis) would be required to detect modifications  of  the uPA 
receptor in bFGF-treated cells. However,  it is also possible 
that small alterations in the glycosylation pattern cause ma- 
jor changes in the affinity of the uPA receptor for its ligand. 
The effect of bFGF on the expression of the uPA receptor 
in endothelial cells is interesting and prompts consideration 
of the mechanism by which bFGF and TGF/31 modulate the 
extracellular uPA activity of these cells. Basic FGF stimu- 
lates both the synthesis of uPA and of a uPA receptor with 
a decreased affinity for its ligand, while having a relatively 
small effect on PAI-1 production. The decrease in receptor 
affinity induced by bFGF may be of physiological signifi- 
cance in the regulation of the cell-bound uPA. bFGF-stim- 
ulated cells will bind uPA in significantly larger amounts 
than nonstimulated cells only when the concentration of uPA 
in their close environment is in the range of the Kd value for 
the low affinity state of the receptor. This is achieved by the 
5-10 fold increase in uPA expression induced by bFGF in en- 
dothelial cells (Saksela et al., 1987; Pepper et al., 1990).  A 
decrease in uPA  synthesis, such as is induced by TGF/31 
(Salsela et al.,  1987; Pepper et al.,  1990),  will result in a 
lower extracellular concentration of the enzyme, and thus in 
a  significant decrease  in the amount of membrane-bound 
uPA. Moreover, the increase in PAI-1 production induced by 
TGF~I will cause the formation of uPA receptor uPA-PAI-1 
complexes,  which  results  in  a  rapid  internalization  and 
degradation ofuPA (Cubellis et al., 1990). Variations in the 
affinity of the uPA receptor might influence this process. It 
is also interesting to note that scuPA concentration in plasma 
is in the Kd range of the high affinity state of the receptor. 
The bFGF-induced increase  in  receptor  number and de- 
crease in receptor affinity therefore result in only a small in- 
crease in binding of  plasma scuPA by bFGF-stimulated cells. 
However, the bFGF- induced increase in uPA production will 
result in a much higher local uPA concentration and thus in 
a significantly higher amount of membrane-bound uPA. For 
example, a five-fold increase in the extracellular uPA con- 
centration will result in a  10-fold increased uPA binding. 
Surface-bound uPA tends to concentrate at focal adhesion 
sites (Hebert and Baker, 1988; Ptllanen et al., 1988). Thus, 
after exposure of cells to bFGF high concentrations of uPA 
will be localized on the membrane of endothelial cells at 
cell-substratum contact sites. The focalization of a high pro- 
teolytic activity on the cell membrane confers upon vascular 
endothelial cells the ability to degrade selectivity the base- 
ment membrane and stromal components and to migrate into 
surrounding tissues to form new blood vessels.  Basic FGF 
is one of the more potent angiogenesis inducers in vitro and 
in vivo. To our knowledge, this is the first demonstration that 
an angiogenic factor upregulates the uPA receptor in en- 
dothelial cells,  thus  increasing the  amount of cell-bound 
uPA. This finding provides a strong argument in favor of a 
key role of the uPA receptor in invasive processes. 
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